Melanoma Matters

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs).TakeawaysClinical Trial DataTreatment EfficacyChapters00:00 Introduction to IGNYTE Study14:04 Response Rate and Safety Profile25:17 RNA-seq Analysis and Toxicity

SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music, books, plays, and television shows. They share personal anecdotes about memorable trips, culinary highlights, gym feats, and their podcasting journey, while also looking ahead to their goals and aspirations for 2026.Keywordsmovies, music, books, plays, television, travel, culinary, podcast, goals, aspirations, Happy Holidays, 2025, reflections, bestTakeaways"Culture"James and Sapna read a lot of books.Theatrical performances can be a delightful family experience - James highly recommends Matilda.There is lots of television watching on both sides of the pond.Traveling memories in 2025.Culinary adventures include Ottolenghi in Richmond.Podcasting is fun when you do it with your best friend.Chapters00:00 Festive Reflections and Year-End Special02:50 Movies and Theater Experiences09:32 Books he read & bought for others to read12:29 Books she read or audio'ed15:56 TV shows we watched in 202520:38 Travel Highlights of the Year22:50 Culinary Adventures and Memorable Meals24:28 Podcast Highlights and Notable Guests32:34 Gym Goalz & PBs

SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-year outcomes of studies such as coBRIM, COMBI-d, and how those compare to 5-year benchmarks from the COLUMBUS study. They explore subgroups and characteristics of favorable (and durable) response, the role of MEK inhibitors on immune activation, and a potential fellow's project (looking at you, Rob?). KeywordsMelanoma, targeted therapy, co-BRIM, COMBI-d, COLUMBUS, immunotherapy, BRAF MEK inhibitors, overall survival, progression-free survival, patient outcomes, cohorts, LDH, organ sitesTakeawaysMEK inhibitors have a complex role in immune response.Normal LDH levels correlate with better patient outcomes.Immunotherapy and targeted therapy can have overlapping patient populations.Sound Bites"We thought we'd do more targeted therapy""Normal LDH is doing better.""Long-term follow-up for targeted therapy."Chapters00:00 Will he or won't he ... James awaits invitation to film premiere04:26 coBRIM 5y FU11:56 COMBI-d 5y FU13:19 LDH subgroups17:26 Normal LDH & <3 organ sites of metastasis 18:07 Invalid analysis & graph ... tsk tsk NEJM 22:36 Fact Check22:40 What's the color of James' t-shirt?25:34 Five-Year Results of BRAF Targeted Therapies28:37 Cure Potential of Adjuvant Targeted Therapy31:34 MEK Inhibition and Immune Activation

Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

SummarySo many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib trials, and discuss side effects associated with this class of therapy. Sapna clears her own confusion regarding the PDUFA date for the NEMO study, and James objects to the way the NEMO abbreviation was derived. Keywordstargeted therapy, MEK inhibitors, METRIC, NEMO, pimasertib, NRAS, BRAF, melanoma, oncology, side effects, clinical trials, drug approval, patient care, cancer treatment, Owen, Dave Solit, Tom Newsom-Davis, Peter HillTakeawaysTargeted therapy is an important area of focus in oncology.MEK inhibitors have been in development for over 15 years.The NEMO trial aimed to evaluate binimetinib for NRAS mutant melanoma.PFS as a primary endpoint in clinical trials.Side effects of MEK inhibitors.The NEMO trial faced challenges in gaining FDA approval despite positive results.Sound Bites"What gets you to an ASCO?"Chapters00:00 Can we get James to go shirtless (req fr Owen the Trainer)04:28 MEK inhibitor trials07:40 Dave Solit is handsome09:50 Side Effects of MEK Inhibitors10:52 Shoutout to Tom Newsom-Davis12:29 Ocular Toxicity and Patient Management16:25 METRIC study19:33 NEMO trial27:16 NEMO and the fate of its PDUFA date29:03 Pimasertib: A New Player in NRAS Mutant Melanoma34:31 Shoutout to Peter Hill & what is the #1 cause of rhabdo in Central London

SummaryIn this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Merrick Ross, a seasoned surgical oncologist, discussing his background, the evolution of surgical practice with regards to melanoma treatment, and the importance of multidisciplinary collaboration. They explore innovations in neoadjuvant therapy, the critical role of pathology in treatment decisions, and the future directions of surgical approaches in metastatic melanoma. They discuss the need for continuous adaptation and collaboration in the ever-evolving landscape of melanoma treatment.Keywordsmelanoma, surgical oncology, neoadjuvant therapy, multidisciplinary care, pathology, metastatic melanoma, melanoma treatment, melanoma surgery, immunotherapy, clinical trialsTakeawaysMerrick Ross shares his journey from Chicago to surgical oncology.Surgery for melanoma has evolved from a primary modality to a multimodal approach.The importance of collaboration between surgical oncologists and medical oncologists is emphasized.Neoadjuvant therapy is seen as a promising area for future research and treatment.Ultrasound imaging is more effective than cross-sectional imaging for assessing nodal basins.The role of pathology is crucial in understanding treatment responses and guiding future therapy.Surgical decisions should be tailored based on individual patient responses and disease characteristics.The need for less aggressive surgical interventions is highlighted as treatment evolves.Merrick emphasizes the importance of understanding tumor biology in surgical decision-making.The conversation underscores the collaborative nature of modern melanoma treatment.Sound Bites"We need to loop in the pathologist.""Surgery has evolved over time.""The decision to be aggressive or not is complex."Chapters00:00 Merrick's upbringing06:30 Evolution of Surgical Oncology for Melanoma12:44 The Role of Sentinel Node Biopsy18:35 Merrick waxes sentimental about neoadjuvant therapy24:47 Collaboration Collaboration Collaboration26:46 The Role of Pathology in Treatment Decisions36:41 Surgical Considerations in Immunotherapy39:44 A lovely closing anecdote about Merrick

SummaryIn this Episode, hosts James & Sapna go into the 7-year follow-up from the randomized phase 3 adjuvant trial of pembrolizumab versus placebo for stage III melanoma, KEYNOTE-054There's a bit too much talk about weightlifting though...

SummaryIn this (longest to-date) episode, James and Sapna delve into the not-so-rare occurence of immune-mediated myocarditis, particularly in the context of immune checkpoint inhibitors. The hosts discuss grading systems, management strategies, and the challenges of diagnosing and treating myocarditis. They emphasize the importance of close follow-up and the need for collaboration with cardiologists.Keywords myocarditis, immune checkpoint inhibitors, cardiology, personalized treatment, grading systemsTakeawaysGrading systems for myocarditis are essential but can be blunt tools.Personalized treatment approaches are crucial for managing myocarditis.Collaboration with cardiologists is vital for effective management.High-dose steroids are often the first line of treatment for myocarditis.There is a need for more prospective data on myocarditis management.Ruxolitinib and abatacept are potential second-line treatments.Monitoring troponin levels can help assess treatment effectiveness.The role of immunosuppressive drugs in myocarditis is still being studied.Early involvement of cardiologists can improve patient outcomes.Understanding the biology of myocarditis can lead to better treatment strategies.

SummaryIn this Part 2 Best of ESMO 2025 episode of Melanoma Matters, hosts James Larkin and Sapna Patel cover the IO Biotech phase 3 trial, Checkmate 238 final results, the Safe Stop trial, the ECOG-ACRIN STAMP trial for Merkel cell carcinoma, and a promising TCR therapy for uveal melanoma. Keywordsmelanoma, cancer research, immunotherapy, clinical trials, ESMO, IO Biotech, Checkmate 238, Safe Stop trial, STAMP trial, uveal melanomaTakeawaysThe IO Biotech trial missed its primary endpoint for PFS.Checkmate 238 confirmed previous findings on RFS and DMFS.The Safe Stop trial suggests early discontinuation of therapy may be safe.STAMP trial shows potential for adjuvant pembrolizumab in Merkel cell carcinoma.Uveal melanoma TCR therapy shows promise.Understanding subgroup analysis in interpreting trial results.Patient management decisions should consider trial limitations and real-world implications.Chapters00:00 Travel Tips and Strategies04:43 IO Biotech Phase 3 Trial Insights12:00 Checkmate 238 Discussion13:10 Navigating Publication Challenges13:59 Checkmate 238 Results15:58 Late Relapses and Follow-Up Strategies17:57 Time of Day of Infusion20:50 Safe Stop Trial: Evaluating Treatment Duration33:12 STAMP Trial: Adjuvant Therapy for Merkel Cell Carcinoma35:05 IMA-203 (Anzu-cel) trial in uveal melanoma

We did it! We recorded a live teaser and a now a timely Best of ESMO 2025 episode... Part 1 of 2!In this episode, hear host James Larkin's favorite childhood vacations (dry skiing, upside down toothbrush hills and Mallorca... so privileged) James & Sapna focus on the 3 neoadjuvant melanoma presentations at ESMO 2025 and take a deep dive in to the results and questions raised for clinic on Monday.

Enjoy this brief behind-the-scenes discussion from ESMO 2025 where we plan our upcoming Best of ESMO episode #ESMO25 #ESMO26 @melanomamatterspod

Enjoy this trailer of Episode 72 - James takes a test!

For the record, we recorded this episode in February 2024 :) better late than never to get it published!In this episode, James has no idea what he's in for. Sapna quizzes James on new drug approvals in hematology & oncology in the year 2024 to see if he can guess the cancer type and mechanism of action.

SummaryIn this episode, hosts James Larkin & Sapna Patel discuss the Women in Melanoma Conference, highlighting its role in fostering networking and collaboration among female oncologists. They reflect on the evolution of the conference, its impact on participants, and the importance of addressing women's issues in oncology. The discussion also touches on the potential for expanding the initiative beyond the U.S. and the value of creating a supportive community for women in the medical field.James reveals a lack of stupid human tricks, Sapna reports on her skill with napkin lipstick blots, and the two fawn over word clouds in the shape of the female form (e.g. Figure 1). Moral of the story? Don't tease, and James is the bigger geek... all aroundKeywordsmelanoma, women in oncology, networking, collaboration, medical conference, women empowerment, survivorship, oncology research, patient care, medical communityTakeawaysThe Women in Melanoma Conference was initiated to address the lack of female representation in oncology meetings.Networking and collaboration are crucial for professional growth in oncology.The conference has evolved to include a broader range of topics relevant to women in the medical field.Participants have expressed feelings of camaraderie and support through the conference.The initiative has led to successful collaborations and publications among attendees.There is potential for expanding the Women in Melanoma initiative internationally.The conference addresses both professional and personal challenges faced by women in oncology.Role-playing exercises have been beneficial for participants in handling difficult conversations.The conference serves as a platform for discussing patient-centered care and survivorship.The success of the initiative may inspire similar programs in other medical specialties.Sound Bites"It's been a lovely forum.""There's no reason this has to stay U.S.""We captured lightning in a bottle here."Chapters00:00 Introduction and Icebreakers02:53 Val Guild & the Inception of WIM06:53 Networking and Collaboration in Oncology10:45 Expanding the Women in Melanoma Initiative14:26 Figure 1. Word Cloud19:07 Fact Check (there are 2 Fact Checks!)29:57 Fact Check Within a Fact Check

You wanted it, we gave it... best of ASCO ...colon...2025 :D In this episode, hosts James and Sapna discuss the key highlights from ASCO 2025, focusing on significant abstracts related to melanoma treatment. They delve into the implications of adrenal insufficiency, the 5 year, final results of Lifileucel, and the ongoing debate between neoadjuvant and adjuvant therapies. The conversation also explores the role of IL-6 in treatment efficacy and the importance of understanding sentinel lymph node positivity. The hosts emphasize the need for innovative clinical trial designs to adapt to emerging data and improve patient outcomes.KeywordsASCO 2025, melanoma, neoadjuvant therapy, adrenal insufficiency, lifileucel, immunotherapy, clinical trials, IL-6, treatment outcomes, cancer researchChapters00:00 Introduction and Overview of ASCO 202503:16 DoorDash!05:43 Key Highlights from ASCO 202508:29 Lifileucel and Its Impact on Treatment10:53 Long-term Outcomes and Toxicity Considerations15:49 Exploring Treatment Efficacy in Refractory Populations17:41 Neoadjuvant and Adjuvant Therapies: A Comparative Analysis21:07 Investigating GM-CSF's Role in Mitigating Toxicity22:36 RELA 098: Insights and Implications25:37 Understanding Sentinel Lymph Node Positivity in Melanoma26:34 Future Directions in Neoadjuvant Therapy Research36:18 Fact Check38:17 Discussion on IPI GM-CSF and Adrenal Insufficiency42:09 Impact of Adrenal Insufficiency on Patients45:06 Future Directions in Neoadjuvant Trials47:26 Wrap-Up and Reflections

Summary In this episode, Sapna Patel and James Larkin engage with Monty Pal from City of Hope, discussing his unique journey into oncology, the significance of the microbiome in cancer treatment, and the impact of diet and lifestyle on patient outcomes. They explore current research, including clinical trials involving fecal microbiome transplants and the potential of specific bacteria to enhance immunotherapy effectiveness. The conversation highlights the evolving landscape of cancer treatment and the promising future of microbiome research in oncology.Keywordsoncology, microbiome, cancer treatment, immunotherapy, diet, clinical trials, kidney cancer, melanoma, fecal microbiome transplant, City of HopeTakeawaysMonty Pal started college at the age of 13, showcasing an unconventional path to medicine.His journey into oncology was influenced by a pivotal decision to switch from engineering to medicine Monty has significantly contributed to the growth of the GU oncology program at City of Hope.The microbiome plays a crucial role in predicting patient outcomes and side effects in cancer treatment.Dietary fiber intake has been linked to improved clinical outcomes in melanoma patients receiving immunotherapy.Random probiotics may not be beneficial and could even be harmful to patients.Research indicates that specific bacteria can enhance the effectiveness of immunotherapy.The future of cancer treatment may involve turning cold tumors into hot tumors using microbiome interventions.TitlesThe Journey of Monty Pal: From Prodigy to OncologistMicrobiome and Cancer: Turd Burglars to TreatmentSound Bites"I started college when I was 13.""Fiber seems to be somewhat interesting."Chapters00:00 Introduction and Introduction of Monty Pal from City of Hope01:42 Monty's Journey to Medicine05:19 GU Oncology at City of Hope10:28 The Microbiome: A New Frontier in Oncology14:52 Microbiome Research and Clinical Outcomes19:21 Lifestyle Factors and the Microbiome23:51 Intervention Strategies: Fecal Microbiome Transplant and Beyond24:35 South Park Episode: Turd Burglars29:58 An Upcoming SWOG trial 32:48 Fact Check

SummaryIn this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Godfather 15 trial, focusing on the neutralizing GDF 15 antibody and its implications in overcoming PD-1 and anti-PD-L1 resistance in solid tumors. They explore the background of GDF-15, its role in immune suppression, and the trial's methodology, including safety and efficacy results. The conversation also touches on the future directions of GDF-15 antibody trials and the importance of understanding treatment resistance in cancer therapy.KeywordsMelanoma, GDF-15, Godfather 15 trial, immunotherapy, cancer research, PD-1, antibody therapy, clinical trials, immune suppression, treatment resistanceTakeawaysThe Godfather 15 trial focuses on neutralizing GDF-15 antibody.GDF-15 is linked to immune suppression in tumors.The trial is a phase 1/2 study with multiple dose levels.Understanding treatment resistance is key in cancer research.The importance of defining refractory cohorts in trials.Biological proof of concept is essential in early studies.Future trials should focus on specific patient populations.Sound bites"This is a phase 1/2 study""This is the biology we're targeting""I think this is obviously just a first step"Chapters00:00 Introduction to the Godfather 15 Trial07:48 Understanding GDF-15 and Its Role in Cancer11:48 Exploring the Study Design and Methodology18:42 Results and Efficacy of the GDF-15 Antibody25:09 Future Directions and Closing Thoughts

SummaryIn this conversation, James Larkin and Sapna Patel discuss the consensus definitions for resistance to immune checkpoint inhibitors, focusing on a recent paper from the Journal of Immunotherapy of Cancer. They explore the complexities of primary and secondary resistance, the importance of defining these terms for clinical trials, and the challenges in trial design and control arms. The discussion emphasizes the need for clear definitions to improve patient outcomes and guide future research in oncology.Keywordsimmune checkpoint inhibitors, cancer treatment, resistance, clinical trials, melanoma, PD-1, adjuvant therapy, response rate, tumor sensitivity, oncologyTakeawaysResistance to immune checkpoint inhibitors is a major challenge in melanoma treatment.Primary resistance occurs when there is no benefit from treatment, while secondary resistance follows initial benefit.Defining resistance is crucial for clinical trials and understanding patient populations.The duration of drug exposure is key in determining resistance types.Clinical trial design must consider the expectations of efficacy in control arms.Investigators should be cautious about the definitions of patient populations in trials.Response rates of 15-20% are considered significant for primary resistance.Secondary resistance may show higher response rates due to residual sensitivity.Clear definitions help in layering data for future research.Collaboration among clinicians, industry, and regulatory bodies is essential for advancing cancer treatment.Sound Bites"It's probably the biggest challenge we now have in clinic.""There's something in the middle.""I think that's where we might need to be there."Chapters00:00 Introduction to Immune Checkpoint Inhibitors and Resistance08:08 Understanding Resistance: Definitions and Scenarios14:47 Primary vs. Secondary Resistance in Clinical Trials22:00 Trial Design and Control Arms in Immunotherapy30:36 Conclusions and Future Directions33:28 outro fade long expo.mp4

SummaryIn this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the recent advancements in understanding and treating cancer cachexia, particularly focusing on the drug ponsegramab. They explore the implications of cachexia across different cancer types, the role of cytokine GDF-15, and the importance of nutrition and physical activity in managing cachexia. They opine on body weight and protein, as per usual.Keywordscancer cachexia, ponsegramab, GDF-15, treatment options, nutrition, clinical trials, melanoma, kidney cancer, pancreatic cancer, weight gainTakeawaysCancer cachexia is a significant issue in various cancers.Ponsegramab shows promise in treating cachexia with meaningful weight gain.GDF15 is a key cytokine elevated in cancer cachexia.Historical treatments for cachexia have included progestins, but newer options are emerging.Nutrition and physical activity are crucial in managing cachexia.Collaboration between academia and industry is vital for drug development.The study of Ponsegramab was conducted across multiple institutions.Cachexia management requires a multifactorial approach.Clinical trials must consider the contributions of all stakeholders.Future research is needed to optimize treatment for cachexia.Sound Bites"This is about cancer cachexia.""We do see the sarcopenia.""Doctors have known about this for 2,000 years."Chapters00:00 Introduction to Cancer Cachexia02:43 Understanding Cachexia in Different Cancers06:41 The Role of GDF-15 in Cancer Cachexia10:39 Clinical Trial Insights on Ponsegramab18:37 Exploring Treatment Implications and Future Directions24:36 Authorship and Collaboration in Cancer Research32:47 Fact Check33:36 Discussion on Cancer Cachexia and Bonsegramab38:14 Historical Context of Treatment in Kidney Cancer42:28 Current Guidelines and Future Directions for Cachexia Treatment

SummaryIn this conversation, Sapna Patel and James Larkin discuss the recent approval of Opdivo Qvantiq, a subcutaneous formulation of nivolumab, and its implications for oncology treatment. They explore the Checkmate 6-7-T study that led to its approval, the efficacy and safety of the new formulation, and the broader regulatory landscape. The discussion also touches on patient perspectives regarding subcutaneous versus intravenous treatment, the potential for future clinical trials, and the importance of patient choice in treatment options.KeywordsOpdivo, Qvantiq, subcutaneous formulation, oncology, Checkmate 6-7-T, nivolumab, patient experience, regulatory approval, cancer treatment, clinical trialsTakeawaysThe approval of Opdivo Qvantiq represents a significant advancement in oncology.Subcutaneous formulations offer convenience and the possibility of home treatment.Patient acceptance of subcutaneous treatment is generally high.The Checkmate 67T study demonstrated the efficacy of subcutaneous nivolumab.Regulatory approval for subcutaneous formulations is becoming more streamlined.Patients may value the social interaction of IV treatments over subcutaneous injections.The future of clinical trials may need to incorporate both subcutaneous and IV options.Understanding patient preferences is crucial for treatment decisions.The role of reimbursement in treatment choice cannot be overlooked.The transition from IV to subcutaneous treatment may impact patient care dynamics.TitlesRevolutionizing Cancer Treatment: Opdivo QvantiqThe Future of Subcutaneous NivolumabSound Bites"It's a no-brainer for patients.""The FDA has taken a view there.""This is not just a flu shot."Chapters00:00 Why does J have Napoleon on his wall?05:36 Dreams of new work office furniture...or gym equipment08:01 CheckMate 67T19:31 Patient Perspectives on Subcutaneous vs. Intravenous Treatment27:43 Regulatory and Approval Insights for Opdivo Qvantig33:30 Future Directions in Clinical Trials38:02 Fact Check38:06 Subcutaneous Treatments in Oncology41:01 Patient Experience and Acceptance of Subcutaneous Treatments44:17 The Shift in Oncology Patient Interactions47:06 Current Landscape of Subcutaneous Drugs in Oncology

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel pick up with Part 2 of 2 - a deep conversation with Claire Turnbull - about the complexities of cancer screening, overdiagnosis, and the role of genetic testing. They explore the implications of screening practices illustrated by the Gilbert Welch paradigm, the challenges faced in patient management, and the future of genetic testing in oncology. The discussion emphasizes the importance of understanding the risks and benefits associated with genetic testing.Keywordsmelanoma, cancer screening, overdiagnosis, genetic testing, patient management, healthcare, public health, cancer research, screening guidelines, cancer predispositionTakeaways• The conversation highlights the importance of understanding the value of cancer screening.• Overdiagnosis is a significant concern in cancer screening practices.• Genetic testing plays a crucial role in identifying cancer predisposition.• Screening should be evaluated rigorously to ensure it benefits patients.• The implications of false positives in screening can lead to unnecessary anxiety for patients.• Healthcare providers must be responsible for interpreting test results they order.• The need for genetic counseling is critical in managing test results and patient care.• There is a growing concern about the overuse of broad genetic testing panels.• Future advancements in technology may improve screening methods.• Public health messaging must address the complexities of cancer screening and genetic testing.Chapters00:00 Clare Turnbull - Part 2 of 204:05 High penetrance, common SNPs, and in betweens07:15 The Gilbert Welch Paradigm12:30 Understanding Lead Time and Overdiagnosis16:11 Randomized Trials in Screening19:59 Consequences of Screening: Overdiagnosis and Anxiety22:22 Debate on Screening Protocols and Their Efficacy25:37 Need for Evidence-Based Genetic Testing31:19 Ripple Effects of Genetic Testing on Families34:00 Fact Check35:47 Genetic testing for ACC?!36:34 Clinical Genetics clinics are NOT just reading guidelines...39:52 David Sackett: Evidence-Based Medicine43:03 Triggering James: (S)he who orders the test reviews & interprets the test

SummaryIn this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome Clare Turnbull, a clinical geneticist in London, to discuss her journey from studying mathematics to medicine, her work in cancer genetics, and the impact of COVID-19 on healthcare. The conversation explores the role of genetic testing in melanoma, the challenges of public health in cancer treatment, and the ongoing effects of the COVID-19 pandemic on cancer care and patient outcomes.Keywordsmelanoma, genetics, COVID-19, public health, cancer treatment, screening, early detection, healthcare, epidemiology, clinical geneticsTakeawaysClare Turnbull transitioned from mathematics to medicine in uni,She has worked extensively in clinical genetics, focusing on cancer genetics.COVID-19 significantly impacted healthcare delivery and cancer treatment prioritization, the effects of which will take a long time to bear out.The importance of genetic testing in melanoma is highlighted, for young onset cases or those with a significant family history.Public health initiatives are crucial for improving cancer outcomes.The pandemic created a bulge in cancer mortality due to delayed diagnoses.Screening for melanoma is essential, but the pick-up rates for genetic mutations are low - a cautionary tale.Sound Bites"A can-do attitude, what can I do to help?""There will be a bulge of mortality.""The pick-up rate's pretty low."Chapters00:00 Opening theme music (My Favourite Dress...The Wedding Present)00:48 Introduction of Guest Clare Turnbull03:27 Clare's Journey in Clinical Genetics05:36 Genomics England, 100K Genomes Project06:58 Clare's extraordinary efforts during COVID12:07 Melanoma and genetic risk(s) versus environmental risk16:28 The Ripple Effects of Genetic Testing on Families

SummaryOn mountain emergencies...Sapna's had them, James denies them...This conversation delves into the treatment options available for patients with advanced melanoma who have progressed after anti PD-1 therapy. The discussion covers various clinical studies, response rates, and the implications of combination therapy post-PD1 progression. James and Sapna conclude that while combination therapies show promise, the responses may not be as robust as those seen in frontline treatments.Keywordsmelanoma, PD-1, treatment, clinical trials, immunotherapy, BRAF, response rates, efficacy, combination therapy, patient outcomesTakeawaysThe conversation focuses on treatment options after PD-1 progression.Clinical studies provide valuable data on post-PD-1 therapies.Response rates for combination therapies are generally higher than monotherapy.BRAF status is a critical factor in treatment decisions.Randomized studies help clarify the efficacy of different treatment approaches.Combination therapy may offer better outcomes for patients post-PD-1.Acquired resistance remains a challenge.TitlesExploring Treatment Options Beyond PD-1The Role of Clinical Trials in Melanoma TherapySound Bites"What to do post PD-1 exposure?""Can you get a response to IPI after PD-1?""The primary endpoint was PFS, not ORR... "Chapters00:00 Opening theme music (My Favourite Dress by The Wedding Present)01:25 Mountain rescue quickfire03:08 Post anti-PD1 studies - the issues04:13 Pires da Silva retrospective study08:53 Olson single-arm prospective study (and yes we see you Jason)10:38 SWOG S1616 randomized ph 2 study16:35 Conclusions17:17 Fact Check

SummaryIn this episode of Melanoma Matters, host Sapna Patel and James Larkin welcome guest Inge Marie Svane to discuss the evolution and future of cancer immunotherapy, particularly focusing on cellular therapy for melanoma. Inge Marie shares her extensive background in the field, the establishment of a cancer immune therapy center in Denmark, and the historical context of cellular therapy. The conversation delves into the current challenges and innovations in T-cell therapy, regulatory hurdles, and the potential for cellular therapy in other solid tumors. The episode highlights the importance of optimizing treatment strategies and the need for collaboration between academia and industry and regulators to improve patient outcomes.Keywordsmelanoma, cancer immunotherapy, cellular therapy, T-cell therapy, checkpoint inhibitors, clinical trials, patient care, regulatory challenges, cancer vaccines, treatment advancementsTakeawaysInge Marie Svane has over 25 years of experience in cancer immunotherapy.She established a center for cancer immune therapy in Denmark.T-cell therapy can benefit patients regardless of checkpoint inhibitor response.Not all patients are suitable for T-cell therapy; age and health status matter.Optimizing T-cell manufacturing processes is crucial for efficacy.Reducing side effects of T-cell therapy is a priority.Regulatory frameworks for cellular therapy are challenging in Europe.Future strategies may include genetic modifications to enhance T-cell function.Cellular therapy shows promise in other solid tumors, but challenges remain.TitlesExploring the Future of Melanoma TreatmentInge Marie Svane on Cancer Immunotherapy InnovationsSound Bites"We need to move forward in all directions.""The system is completely untrained for academia."Chapters00:00 Introduction of Guest Inge Marie Svane05:37 Historical Perspective on Cellular Therapy for Melanoma09:04 Optimizing T-Cell Therapy: Challenges and Innovations20:50 Prospects for Cellular Therapy in Other Solid Tumors

Welcome to Season 2! In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin engage with Michael Atkins from Georgetown University to discuss the advancements in melanoma and kidney cancer treatments, particularly focusing on immunotherapy and cytokine treatments. They explore the groundbreaking DreamSeq trial that compares immunotherapy and targeted therapy in 1L melanoma. Keywordsmelanoma, immunotherapy, cytokines, DreamSeq trial, kidney cancer, cancer treatment, checkpoint inhibitors, complete response, T cells, cancer researchTakeawaysThe introduction of checkpoint inhibitors has revolutionized cancer treatment.Cytokines like IL-2 have a historical role but are being reevaluated in modern therapy.Complete responses to therapy are crucial for durable benefits in cancer treatment.The DreamSeq trial highlights the superiority of immunotherapy over targeted therapy in certain patient populations.Understanding the tumor microenvironment is key to improving immunotherapy outcomes.The need for better imaging techniques to assess treatment responses is critical.Aggressive disease patients may require different treatment strategies than those with less aggressive disease.The importance of patient advocacy in pushing for effective cancer treatments.Future research should focus on enhancing the efficacy of immunotherapy in various cancers.Sound Bites"I love talking about melanoma and immunotherapy.""Immunotherapy was better in all the subgroups.""We need to raise the bar above nivo-IPI."Chapters00:00 Introduction to Melanoma and Immunotherapy10:21 The Role of Cytokines in Cancer Treatment17:02 The DreamSeq Trial Explained27:20 Comparing Immunotherapy and Targeted Therapy in Kidney Cancer37:18 Final Thoughts on Immunotherapy's Future

Time to exhale... and reflect upon 2024.In this episode, hosts Sapna Patel and James Larkin reflect on their professional and personal experiences from 2024, discussing highlights, lowlights, and the impact of loss in the medical community. They share their intentions and goals for 2025, emphasizing personal bests, leadership , and the importance of friendships. The conversation also touches on cultural reflections, including movies, books, and music, culminating in heartfelt poetry for the New Year.Keywords2025 intentions, professional highlights, personal growth, medical community, cultural reflections, leadership challenges, loss, achievements, goals, aspirationsTakeawaysThe importance of being in the arena and taking risks.FDA approval of lifileucel marks a significant milestone.Loss in the medical community deeply affects personal and professional lives.Transitioning to new roles can bring self-doubt and challenges.Celebrating achievements is crucial for personal growth.Setting intentions for the new year can guide personal and professional goals.Friendships are foundational to our well-being and happiness.Looking ahead with optimism.TitlesReflections on 2024: Intentions for 2025Navigating Professional Highlights and LowlightsSound Bites"I want to read the Malcolm Gladwell book.""Cheers to 2025!""It's been one hell of a 365."Chapters00:00 2024 Reflections and 2025 Intentions03:41 Professional Highlights and Lowlights06:02 Personal Growth and Career Transitions08:17 Leadership and Self-Doubt10:44 Memorable Experiences and Connections12:16 Personal and Professional Intertwining12:37 Looking Ahead to 202517:18 Personal Bests: A Metaphor for Life18:19 Literary Adventures: Books and Insights19:07 Cinematic Experiences: Movies of the Year26:05 Looking Ahead: Goals for 202532:06 Reflections and New Year Wishes33:55 Fact Check

SummaryFavorite holiday songs... perhaps unexpectedly one of our hosts faves is Christmas Card From a Hooker in Minneapolis ... guess which? In another Best of 2024 episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss key findings from the Society for Melanoma Research (SMR) meeting. They spotlight the TIL for CNS mets study, KEYMAKER U02 Substudy 02D, IMA203, KeyVibe, and the MERLIN 001 study. They emphasize the importance of understanding patient eligibility for clinical trials and the challenges of translating trial results to real-world patient care.Keywordsmelanoma, cellular therapy, brain metastases, clinical trials, treatment efficacy, sentinel lymph node biopsy, immunotherapy, melanoma research, patient care, oncologyTakeawaysThe pilot trial of life elusive cellular therapy shows feasibility and safety.Inclusion criteria for clinical trials often exclude real-world patients.KEYMAKER U02 Substudy 02D did not demonstrate significant activity in brain metastases.IMA203 is a non-surgical cellular therapy trial option for patients with advanced melanomaAdjuvant TIGIT plus PD-1 therapy is unlikely to be effective in melanoma (KeyVibe)Gene expression tests may not reliably identify patients who can forgo sentinel lymph node biopsies (MERLIN 001).Chapters00:00 Festive Greetings and Holiday Tunes02:44 TIL for CNS Mets09:04 KEYMAKER U02: Substudy 02D12:51 IMA20316:48 KeyVibe19:27 MERLIN 00123:28 Happy Holidays!

SummaryVoicing punctuation #2 ...In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss their second episode in the "Best of 2024" series and review the highlights from the 2024 ESMO Congress. They discuss the final analysis of CheckMate 067, long-term data from KEYNOTE 006, DMFS from NADINA, and the KEYMAKER U02 Substudy 02C. The conversation also covers results from CheckMate 76K and KEYNOTE 716, as well as an exploratory analysis from KEYNOTE 054.KeywordsESMO 2024, melanoma, CheckMate 067, KEYNOTE 006, NADINA, KEYMAKER U02, CheckMate 76K, KEYNOTE 716, KEYNOTE 054, immunotherapyTakeawaysThe final analysis of CheckMate 067 shows sustained overall survival benefit and demonstrates cure is possible. Melanoma-specific survival is becoming a critical endpoint in trials.Long-term data from KEYNOTE 006 confirms durable benefit of pembrolizumab.The NADINA study presents sustained event-free survival & DMFS benefits.KEYMAKER U02 highlights the potential of neoadjuvant platforms.CheckMate 76K and KEYNOTE 716 show consistent results in adjuvant settings.The importance of staffing clinical trials for long-term follow-up is emphasized.New endpoints like PRFS2 are being explored in studies.Chapters00:00 Introduction and Holiday Reflections02:46 Key Presentations from ESMO 202403:44 CheckMate 067 Final, 10-Year Analysis07:38 KEYNOTE 006: 10-Year Data12:34 NADINA DMFS16:25 KEYMAKER U02: Substudy 02C (Umbrella Neoadjuvant Arms 4, 5, 6)21:07 CheckMate 76K & KEYNOTE 71625:03 KEYNOTE 054: 7 Year Follow-up

SummaryVerbalizing punctuation for laughs...background wood noises ... and out of office replies get things started. In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel record their first in a series of "Best of 2024" and review highlights from the ASCO Annual Meeting. They focus on 4 significant trials: NADINA, COMBI-AD, KEYNOTE 942, and RELATIVITY 048. James & Sapna discuss the implications of these studies on the melanoma landscape, the importance of long-term follow-up data, and share some light-hearted moments about out-of-office messages.KeywordsASCO 2024, melanoma, NADINA trial, neoantigen therapy, checkpoint blockade, out of office messages, long-term follow-up, immunotherapyTakeawaysOut-of-office messages can be creative and memorable.The NADINA trial showed a high major pathologic response rate of 60%.Patient inclusion and trial design in clinical trials can critically affect outcomes (COMBI-AD).The KEYNOTE 942 trial demonstrated encouraging trends for overall survival.Triplet checkpoint blockade shows promising PFS results (RELATIVITY 048).TitlesASCO 2024 Highlights: Melanoma Trials ReviewedNADINA, COMBI-AD, KN 942, RELA 048Chapters00:00 Introduction and Icebreakers06:24 ASCO 2024 Highlights: NADINA Trial13:39 Long-Term Follow-Up: COMBI-AD Study21:16 Individualized Neoantigen Therapy: KEYNOTE 94230:23 Triplet Checkpoint Blockade: RELATIVITY 04831:11 Fact Check Best of 2024: ASCO31:16 FDA Guidelines on Phase 3 Trials (Listening Series)

In this episode we are calling VIBE - Voicing Interesting Bits from Everyone - we want to hear from YOU!We've opened an email address to field your questions, concerns, feedback and input. <[email protected]>While we cannot answer specific patient case questions, this is a great forum to clarify any questions around the data. Our plan is to record an episode discussing the questions we receive. [email protected]

Summary In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome surgical oncologist Mark Faries to discuss the evolution of surgical practices in melanoma, particularly focusing on sentinel lymph node biopsy and the implications of recent clinical trials. They explore the historical context of lymph node surgeries, the significance of nomograms in predicting patient outcomes, and the latest NCCN guidelines regarding clinic l stage II melanoma. They also delve into the emerging role of neoadjuvant therapies and the planned MSLT-3 trial, exploring the balance between effective treatment and minimizing surgical interventions. The discussion highlights the importance of staging information and the potential immunosuppressive effects of surgery, concluding with reflections on the collaborative nature of oncology care. Takeaways The significance and historical context of sentinel lymph node biopsy in melanoma treatment. NCCN recommendations are evolving regarding sentinel lymph node biopsies. Neoadjuvant therapies are changing the surgical landscape. MSLT-3 aims to explore less invasive surgical options. Surgery has immunosuppressive effects that need consideration. Accurate staging information is a factor in decisions about treatment. Collaboration between surgical and medical oncologists is fun! Keywords melanoma, surgical oncology, lymph nodes, sentinel lymph node biopsy, MSLT trials, adjuvant therapy, nomograms, NCCN guidelines, neoadjuvant therapy, immune suppression Titles Navigating Melanoma: Insights from Surgical Oncology The Evolution of Sentinel Lymph Node Surgery Sound Bites "No tumor is resistant to formaldehyde." "Surgery is the gold standard." "We need that staging information." Chapters 00:00 Introduction and Welcome to Special Guest, Mark Faries 06:06 The Evolution of Lymph Node Surgery 09:07 MSLT Trials: Insights and Outcomes 11:59 Current Practices in Sentinel Lymph Node Biopsy 15:02 Adjuvant Therapy and Its Implications 21:09 NCCN Guidelines and Clinical Stage II Disease 24:19 MSLT-3: A New Era in Melanoma Surgery 26:52 The Role of Immune Suppression with Surgery

Summary In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel welcome their first live guest, Toni Ribas. The conversation covers the evolution of melanoma treatments, the challenge of treatment resistance, and the importance of clinical trials. The episode emphasizes the need for continuous innovation and the importance of understanding the complexities of the immune system in cancer therapy. Takeaways Toni shares his journey in oncology, highlighting the importance of scientific exploration. Resistance to therapies remains a major challenge in melanoma treatment. Clinical trials are essential for understanding treatment efficacy and developing new strategies. Chasing complete responses in treatment is crucial for long-term patient outcomes. Patients should not be seen as failing treatments; rather, the focus should be on improving treatment strategies. Understanding the differences between mouse and human immune systems is vital for effective treatment development. Keywords melanoma, oncology, immunotherapy, targeted therapy, clinical trials, resistance, checkpoint inhibitors, cancer treatment, patient care, medical research Sound Bites "We need to do clinical experimentation." "We've democratized treatment of melanoma." Chapters 00:00 Introduction of Guest Toni Ribas 03:29 Toni Ribas' Journey in Oncology 05:44 A Brief History of Melanoma Treatment Before it was Cool 08:26 Understanding Resistance in Melanoma Therapy 11:25 The Role of Targeted Therapy and Immunotherapy 14:35 Clinical Trials and Lessons Learned 17:47 Chasing Complete Responses in Melanoma 20:18 The Future of Melanoma Treatment 22:49 Conclusion and Reflections

SummaryIn this episode of Melanoma Matters, James tells us about his path to oncology (thank you, Emma) via John Newsom-Davis, the Jeremy Bentham pub, and Hammersmith Hospital.Later, hosts Sapna Patel and James Larkin discuss the COLUMBUS 7-year data of targeted therapy for metastatic melanoma - treatment efficacy, toxicity, and long-term patient management. They explore the nuances of treatment strategies, the importance of biomarkers, and the challenges of monitoring long-term patients on targeted therapies.TakeawaysTime to next therapy is a valuable metric for assessing treatment success.Long-term treatment decisions should consider patient quality of life.Biomarkers are crucial for determining the duration of targeted therapy.Compliance in clinical trials may not reflect real-world scenarios.Monitoring for long-term toxicity is necessary for patients on extended therapy.The combination of BRAF and MEK inhibitors may improve tolerability despite the COLUMBUS study showing a higher toxicity rate in the combination arm.Congratulations to the European colleagues who led and executed this trial.KeywordsBRAF MEK, targeted therapy, COLUMBUS study, melanoma, treatment efficacy, toxicity, long-term care, patient managementTitlesExploring the COLUMBUS 7-Year DataOncology Journeys: Personal Stories and InsightsSound Bites"We need to know even the low-grade toxicities.""There's nothing wrong with improving side effects.""Kudos to our mainland European colleagues."Chapters00:00 Introduction 06:12 COLUMBUS 7-Year Overview12:15 Historical context on study arms17:55 Long-Term Treatment Considerations21:29 Desperate... for a Biomarker23:43 Any insights into development of CNS disease?30:47 Fact Check for COLUMBUS 7-Year follow-up32:50 Time to End of Next Line of Treatment in COLUMBUS (akin to PFS2)35:32 Toxicity & Discontinuation Rate in COLUMBUS

Teaser: Find out Allison's favorite body part, had she been an orthopedic surgeon (and James' 2nd favorite.. from the movie Sleeper)SummaryIn this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome Dr. Allison Betof-Warner, Director of the Advanced Melanoma Program at Stanford University. The conversation explores Dr. Betof-Warner's journey into oncology, her passion for CrossFit, and the significant role of exercise in cancer prevention and treatment. They discuss the emerging field of exercise oncology, the importance of strength training for cancer patients, and the latest advancements in cellular therapy for melanoma, particularly in patients with brain metastases. Hot take: physical activity is a vital component of cancer treatment. Keywordsmelanoma, oncology, exercise oncology, cancer prevention, cellular therapy, CrossFit, strength training, TIL therapy, patient care, health and wellnessTakeawaysExercise is crucial throughout the cancer journey, from prevention to treatment.The field of exercise oncology is growing, focusing on the benefits of physical activity for cancer patients.Strength training is now recommended for cancer patients to maintain function and prevent cachexia.Patients should be encouraged to engage in regular physical activity, even during treatment.Research shows that exercise can improve tumor vascular structure and enhance chemotherapy delivery.The safety of exercise during cancer treatment has been increasingly supported by research.Cellular therapy is a promising area of research for melanoma, especially in patients with brain metastases.Patient education regarding exercise during treatment is important.A multidisciplinary approach to cancer care, including physical therapy, is essential for optimizing patient outcomes.TitlesThe Role of Exercise in Cancer TreatmentCellular Therapy in Melanoma with Brain MetastasisSound Bites"I shifted the direction of my research, did my PhD in cancer research.""Exercise spans the cancer journey.""Exercise helps prevent cancer cachexia."Chapters00:00 Introduction 03:24 Allison's Journey to Oncology and CrossFit06:32 The Intersection of Exercise and Cancer09:33 Exercise Oncology: Benefits and Guidelines19:22 Safety and Efficacy of TIL Therapy for CNS disease25:22 Patient Exercise During Cell Therapy

SummaryGulf oysters and FATE get a shoutout in this episode of Melanoma Matters. Hosts James Larkin and Sapna Patel discuss the ADAPT-IT study, focusing on adaptive dosing strategies in immunotherapy for melanoma. They explore the study's design, results, and implications for clinical practice, including the potential for reduced dosing based on early response assessments. KeywordsADAPT-IT study, immunotherapy, melanoma, adaptive dosing, clinical efficacy, treatment response, toxicity management, cancer researchTakeawaysThe ADAPT-IT study explores adaptive dosing in immunotherapy.68% of patients showed favorable anti-tumor effects after two doses.Early response assessments can guide treatment decisions.The study suggests that two doses may be sufficient for some patients.There is potential for one dose to be effective in certain cases.Reimbursement policies may influence treatment strategies.Correlative studies provide insights into treatment efficacy.Management of toxicity is crucial in immunotherapy.The conversation highlights the importance of clinical intuition.Future research may refine dosing strategies further.Sound Bites"Is two cycles enough?""68% had a favorable anti-tumor effect.""Could one dose be enough?"Chapters00:00 Introduction to the ADAPT-IT Study04:12 FATE v non-FATE06:03 Clinical Implications of Early Response Assessment09:02 Results and Efficacy of the Study11:50 Discussion14:18 Exploring the Role of LDH in Treatment Decisions17:32 Correlative Studies and Future Directions20:14 Toxicity and Management Strategies22:58 Correlatives (ctDNA)30:54 Bit of good news about NADINA

Summary In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Bettina Ryll, founder of the Melanoma Patient Network Europe (MPNE). Bettina shares her personal journey from being a physician to becoming a patient advocate after her husband's battle with metastatic melanoma. The conversation explores the evolution of patient support networks, the challenges faced in healthcare systems, and complex adaptive systems. Bettina emphasizes the need for systemic change to improve patient access to treatments and highlights the importance of understanding the interconnectedness of healthcare, economics, and patient outcomes. Keywords melanoma, patient advocacy, healthcare systems, immunotherapy, patient networks, Bettina Ryll, MPNE, clinical trials, healthcare access, systemic change Takeaways Bettina Ryll founded MPNE after her husband's battle with melanoma. Patient networks are crucial for sharing knowledge and support. Understanding the healthcare system is key to advocating for patients. Immunotherapy presents complex challenges that need addressing. Systemic change is necessary for improving patient access to treatments. The pharmaceutical landscape is influenced by economic factors. Patients should not be treated as victims of their circumstances. Action is often more effective than extensive planning. Collaboration and community (and ferocious energy) are essential for driving change. Sound Bites "I just started explaining science." "We are sentinels for issues." "We must be standing for something." Chapters 00:00 Introduction to Bettina Ryll 06:19 The Formation of Melanoma Patient Network Europe 11:51 Understanding Patient Needs and Systemic Issues 17:54 Challenges in Immunotherapy and Clinical Trials 23:47 Healthcare and Patient Access as Complex Adaptive Systems 29:25 The Role of Community and Collaboration in Change

SummaryIn this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Jedd Wolchok, a prominent figure in oncology, to discuss his journey into the field, the evolution of immunotherapy, particularly the Checkmate-067 trial, and the long-term outcomes for melanoma patients. The conversation highlights the importance of collaboration in clinical trials, the significance of understanding treatment decisions, and the future of melanoma treatment with a focus on biomarkers and patient follow-up. The discussion also reflects on the profound impact of Checkmate-067 on patient care and the oncology community.Keywordsmelanoma, immunotherapy, Checkmate-067, oncology, patient outcomes, long-term follow-up, biomarkers, cancer treatment, clinical trials, survivorshipTakeawaysJedd Wolchok's journey into oncology was influenced by family experiences with cancer.The Checkmate-067 trial was a pivotal moment in melanoma treatment.Collaboration among researchers is crucial for successful clinical trials.Long-term follow-up data from Checkmate-067 shows promising outcomes for patients.Understanding residual abnormalities in imaging is essential for treatment decisions.The need for biomarkers to assess immune system activation is critical.Patient follow-up strategies should be tailored to individual needs.The impact of Checkmate-067 extends beyond melanoma to other cancers.The evolution of immunotherapy has changed the landscape of cancer treatment.Mentorship and collaboration are key to advancing oncology research.TitlesReflections on a Career in OncologyThe Impact of Checkmate-067 on OncologySound Bites"This is something that we need to be doing.""We need to incorporate the symptomatic meaning.""Not every residual area of abnormality is cancer."Chapters00:00 Introduction to Melanoma Matters and Guest Background03:25 Journey into Oncology and Early Influences06:26 The Evolution of Immunotherapy: Checkmate-06709:14 The Significance of Phase One Trials12:25 Long-term Outcomes and Implications of Checkmate-06715:09 Understanding Treatment Responses and Patient Management18:06 The Future of Oncology: Biomarkers and Precision Medicine21:19 Survivorship and Patient Follow-up Strategies24:21 Reflections on the Impact of Checkmate-06727:24 Closing Thoughts and Acknowledgments

SummaryIn this episode of Melanoma Matters, hosts James Larkin and Sapna Patel welcome Dr. Andreas Schmitt to discuss various aspects of melanoma treatment, including the importance of supplementary data in clinical trial reports, the implications of the TRICOTEL study, and the role of PD-L1 as a biomarker. The conversation highlights the significance of peer review and academic collaboration in oncology, as well as the impact of regulatory decisions on patient treatment options. The episode concludes with a discussion on the findings of the republished TRICOTEL study and the importance of inquiry in medical practice.Keywordsmelanoma, oncology, clinical trials, PD-L1, TRICOTEL study, symptomatic brain metastasis, supplementary data, peer review, academic collaboration, cancer treatment, biomarkersTakeawaysThe importance of looking at supplementary data in clinical trials is a recurring theme in this podcast.The TRICOTEL study revealed significant findings regarding treatment for symptomatic brain metastasis, but there was controversy over the coding of these patients as symptomatic.Peer review and academic collaboration are crucial in addressing discrepancies in clinical data.PD-L1 expression may not be a reliable biomarker for treatment decisions in melanoma.Regulatory decisions can impact patient access to effective treatments.The objective response rate in the TRICOTEL republication was lower than in the initial (retracted) report.Inquiring and questioning data is an essential feature of an intrepid (F)ellow.Continuous reading and inquiry are vital for oncologists to stay informed. Sound Bites"Why I'm an oncologist?""Look at the supplementaries!""We redesigned the SWOG S2000 study after the TRICOTEL presentation to drop the asymptomatic cohort."Chapters00:00 Introduction and Lighthearted Banter00:30 Meet the Guests: Andreas Schmitt01:34 Always read the Supplemental Appendix!06:31 The TRICOTEL Controversy Unveiled10:43 Symptomatic Cohort in TRICOTEL18:35 Peer Review in Publications20:20 Republication of the TRICOTEL data22:08 Editorial(s) on PD-L1 as a Biomarker32:38 Concluding Thoughts on PD-L1

Summary*Warning* with apologies! There is a change in sound at 11:11 mark that might necessitate a lower volume output. Hosts James Larkin has a beef with the first word of the cemiplimab + fianlimab JCO publication. He's living vicariously through Sapna's snowboarding plans for the season (if the record high temps ever stop). They continue to struggle with Farenheit to Centrigrade conversion. In this episode of Melanoma Matters, James and Sapna discuss the recent publication on cemiplimab and fianlimab, focusing on their efficacy in various patient cohorts, particularly those who are PD-1 naive. They discuss if all LAG-3 antibodies are created equal, and one host is busted for not reading the Supplementary Appendix to the publication. Keywordsmelanoma, cemiplimab, fianlimab, LAG-3, PD-1, cancer therapy, clinical trials, efficacy, adverse events, immunotherapyTakeaways Objective response rates are promising in various cohorts. Semiplimab and Thiamlimab show efficacy in PD-1 naive patients. The study highlights the need for larger randomized trials. Comparative efficacy of LAG-3 therapies remains to be seen. Adverse events like infusion reactions are noteworthy. The conversation emphasizes the importance of ongoing research. Understanding patient selection criteria is crucial for interpreting results. The hosts discuss the implications of the findings for future treatments. There is excitement about the potential of these new therapies. The episode underscores the evolving landscape of melanoma treatment. ALWAYS READ THE SUPPLEMENTARY APPENDIXTitlesUnderstanding LAG-3 Therapies in MelanomaThe Promise of LAG-3 in Advanced MelanomaSound Bites"Objective response rate in all these cohorts looks good""This is a paper about a novel (anti) LAG- 3 + PD-1 combination""The objective response rate is topping 50%"Chapters00:00 Introduction 04:56 Discussion on Cemiplimab and Fianlimab07:48 Exploring Phase One Trial Data10:56 Comparative Analysis of LAG-3 Therapies11:11 *Warning* Volume / Sound Change14:16 Understanding Patient Cohorts and Response Rates16:50 Comparative Analysis of Treatment Options20:10 Safety and Adverse Effects of New Combinations23:11 Future Trials with This Combination

SummaryLeft siding, Starfishing, and Superstitions! We make a hidden shoutout to Owen and a subtle callout to Zayd ... if you're listeningIn this episode of Melanoma Matters, hosts Sapna Patel and James Larkin delve into the Keynote 006 study, exploring its implications for melanoma treatment, long-term follow-up, and patient outcomes. The conversation highlights the importance of understanding CR versus PR in treatment and the need for better data collection on re-treatment. The episode concludes with reflections on the challenges of conducting such extensive research and the importance of collaboration in the field.Keywordsmelanoma, immunotherapy, pembrolizumab, Keynote 006, patient outcomes, superstitions, sleep habits, treatment duration, toxicity, CR vs PR, PFS vs TTPTakeawaysThe Keynote 006 study provides valuable data on melanoma treatment.Long-term follow-up is crucial for understanding treatment efficacy.Re-treatment with pembrolizumab can be beneficial for certain patients.Understanding the difference between CR and PR is essential in treatment discussions.Toxicity profiles of treatments need to be monitored over time.Time to progression is a more relevant metric than PFS in some cases.Collaboration among researchers is vital for advancing melanoma treatment.Sound Bites"It's better to have a CR than have a PR.""We need to stop doing PFS in long-term follow-ups.""Patients are dying of other causes, not melanoma."Chapters00:00 Introduction and Greetings03:25 Left side and Starfish06:43 Superstitions and Their Impact on Behavior09:35 Keynote 006 Study Overview12:26 Long-term Follow-up and Treatment Insights15:38 Re-treatment and Patient Outcomes18:24 CR vs PR and Treatment Duration25:07 Final Thoughts and Acknowledgments28:21 Call to fellows (hearing us, Zayd?) 36:14 PFS v. TTP

SummaryMore stories about medical emergencies! In this conversation, James Larkin and Sapna Patel discuss the complexities of tumor dynamics in patients treated with pembrolizumab beyond disease progression. They share personal anecdotes about medical emergencies on flights, which lead into a deeper exploration of treatment strategies and clinical trial methodologies. The discussion emphasizes the importance of understanding patient responses to treatment, the limitations of traditional assessment tools like RESIST, and the need for careful consideration in trial designs to avoid premature conclusions about new therapies.Keywordstumor dynamics, pembrolizumab, treatment beyond progression, medical emergencies, clinical trials, cancer treatment, immunotherapy, patient care, melanoma, PD-1TakeawaysTreatment beyond progression can yield clinical benefits.RECIST criteria may not accurately reflect patient responses to immunotherapy.Understanding disease trajectory is crucial in treatment decisions.Clinical trials must be designed to account for patient variability.The importance of patient monitoring during treatment is emphasized.AI could revolutionize tumor assessment in clinical practice.Caution is advised when interpreting early trial results.Stepwise progression in trial design can save resources.TitlesInnovations in Tumor AssessmentCautionary Tales in Cancer ResearchChapters00:00 Medical Emergencies on Flights10:46 Treatment Beyond Progression in Cancer16:49 Clinical Trials and Patient Outcomes26:47 Cautionary Tales in Cancer Treatment

Summary In this episode of Melanoma Matters, Sapna and James discuss the importance of looking at Figure 1. They talk about in-flight medical emergencies, and James recalls a scene of carnage ... "blood everywhere." They delve into the complexities of mucosal melanoma, discussing its unique characteristics, treatment options, and the latest research findings. They share personal anecdotes from their medical experiences, emphasizing the importance of understanding the nuances of this melanoma subtype. The conversation covers the efficacy of checkpoint inhibitors, the significance of various studies, and considerations for adjuvant and neoadjuvant therapies. The hosts also highlight the need for tailored approaches in treating mucosal melanoma patients, given the disease's heterogeneity and geographical variations. Keywords Mucosal Melanoma, Checkpoint Inhibitors, Adjuvant Therapy, Neoadjuvant Therapy, Oncology, Cancer Treatment, Medical Stories, Clinical Trials, Patient Care, Melanoma Research Takeaways Mucosal melanoma is a unique subtype that requires specific attention. Checkpoint inhibitors have shown efficacy in treating mucosal melanoma. Understanding geographical variations is crucial in melanoma treatment. Clinical trials often exclude mucosal melanoma patients, impacting data. Adjuvant therapy may be beneficial but is not universally applicable. Neoadjuvant therapy could be a reasonable option for certain patients. Response rates vary significantly based on the anatomical site of the melanoma. Patient performance status plays a critical role in treatment decisions. The importance of thorough data collection in clinical trials cannot be overstated. Personal anecdotes from physicians highlight the unpredictable nature of medical emergencies. Titles Emergency Medical Stories: A Doctor's Perspective Comparative Studies in Mucosal Melanoma Treatment Sound Bites "I think we actually missed this figure." "Always look at Figure 1." Chapters 00:00 Introduction to Mucosal Melanoma 05:21 Anecdotes from the Medical Field 08:19 Understanding Mucosal Melanoma 14:25 Sapna and James look at Figure 1 20:21 Comparative Analysis of Studies 26:30 Adjuvant and Neoadjuvant Therapies for Mucosal Melanoma

SummaryJames' favorite moments from #ESMO24 include footie and a not-so-chance encounter with NEJM Editor-in-Chief, Eric Rubin. In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Relativity 020 study, which focuses on Nivo Rela after PD-1 exposure in melanoma patients. They reflect on their experiences at ESMO, including networking and memorable moments, before diving into the details of the study, including patient cohorts, treatment efficacy, and the challenges faced in clinical trials. The conversation also touches on the role of CTLA-4 therapies and the complexities of treatment sequencing in melanoma care.Keywordsmelanoma, ESMO, Relativity 020, Nivo Rela, PD-1, CTLA-4, clinical trials, patient access, immunotherapy, oncologyTakeawaysThe Relativity 020 study explores Nivo Rela after PD-1 exposure in melanoma.Networking at ESMO is crucial for sharing insights and experiences.Patient access to treatments is a significant challenge in clinical trials.The efficacy of Nivo Rela in heavily pretreated patients is limited.CTLA-4 therapies show low response rates in PD-1 refractory patients.Understanding treatment sequences is essential for optimizing patient outcomes.The importance of academic trials in addressing knowledge gaps in melanoma treatment.Elevated LDH levels are a concerning biomarker in treatment response.Collaboration among investigators is vital for advancing melanoma research.The conversation highlights the need for ongoing research and trials in melanoma. Chapters00:00 Introduction and ESMO Highlights03:30 Reflections on ESMO 202406:21 The Relativity 020 Study Overview09:17 Patient Perspectives and Clinical Trials12:20 Challenges in European Clinical Trials15:36 Efficacy of NIVO-RELA in Refractory Melanoma18:40 Discussion on CTLA-4 Therapies21:21 Future Directions in Melanoma Treatment

Summary In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel reflect on their experiences at ESMO 2024 and the importance of face-to-face meetings. But then James pops the balloon by commenting on the carbon footprint of the airplane travel. They go on to discuss the phase three trial comparing ipilimumab doses in melanoma and delve into the trial's design, results, and implications for clinical practice. The conversation also covers the significance of long-term follow-up data, the challenges of pooled analyses, and the need for improved clinical trial design to capture more nuanced survival data. Keywords melanoma, ipilimumab, clinical trials, ESMO, cancer treatment, immunotherapy, overall survival, phase three trial, patient care, research Takeaways The value of face-to-face meetings is irreplaceable. The IP10 trial was crucial for understanding ipilimumab dosing. Access to effective treatments can be limited by bureaucracy. Long-term follow-up data is essential for understanding treatment efficacy. Re-challenging with ipilimumab can be effective in certain cases. Pooled analyses can provide insights but have limitations. Clinical trial design should capture more than just overall survival. Data quality varies between industry and academic studies. Understanding the mechanisms of resistance is key to treatment. Dosing strategies in immunotherapy require careful consideration. Sound Bites "My favorite is just being within vibrational energy of people you hold dear." "We had a queue of patients waiting to go into the study." "This study was really trying to answer in a prospective way." Chapters 00:00 Introduction and Icebreaker Moments 03:41 Discussion on the Phase Three IP10 Trial 06:15 Trial Design and Results Overview 09:04 Clinical Implications and Treatment Access 12:01 Re-challenging with Ipilimumab 14:55 Long-term Follow-up and Survival Rates 18:07 The Importance of Data Quality in Trials 20:19 Conclusions and Final Thoughts

SummaryIn this episode, James needs some sun cream! The conversation discusses the outcomes of post-recurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in the Checkmate 238 trial. The study found that early recurrences were associated with worse outcomes compared to late recurrences. Patients who recurred early had shorter progression-free survival and overall survival compared to those who recurred later. The subsequent therapy received by patients varied, with some receiving chemotherapy, immunotherapy, or targeted therapy. The data on subsequent therapy were not well-categorized, making it difficult to draw definitive conclusions. The conversation highlights the challenges of treating patients who recur despite adjuvant therapy and the need for further research in this area.Keywordsmelanoma, adjuvant therapy, recurrence, systemic therapy, checkpoint inhibitors, progression-free survival, overall survival, subsequent therapyTakeaways Early recurrences in melanoma patients who received adjuvant checkpoint inhibitor therapy are associated with worse outcomes compared to late recurrences. The subsequent therapy received by patients varied, with some receiving chemotherapy, immunotherapy, or targeted therapy. The data on subsequent therapy were not well-categorized, making it difficult to draw definitive conclusions. Treating patients who recur despite adjuvant therapy remains a significant challenge in clinical practice.Sound Bites"Early recurrences in melanoma patients are a bad thing.""Sensitivity to anti-PD-1 drugs is not black and white; there are gray zones.""The subsequent therapy received by patients varied, with some receiving chemotherapy, immunotherapy, or targeted therapy."Chapters00:00 Introduction and Personal Experiences with Sunburns05:00 Overview of Checkmate 238 and Outcomes after Recurrence09:58 Early versus Late Recurrences and Treatment Outcomes16:58 Analysis of Recurrence Patterns and Subsequent Therapies23:58 Discussion on Anatomic Sites of Recurrence29:27 Conclusion and the Importance of Further Research30:30 Fact Check31:54 The Search for Clinically Usable Biomarkers32:20 Acknowledging Efforts

Summary (Coach) Owen is in a seriously bad mood with James at the moment! But James is back in pull-up form and can do an impressive number of strict pull-ups... In this episode, Sapna Patel and James Larkin discuss the LEAP 004 and LEAP 003 studies, focusing on the combination of lenvatinib and pembrolizumab in treating melanoma, particularly in patients who are refractory to PD-1 inhibitors. They explore the efficacy, safety, and implications of these studies, as well as the challenges in treatment guidelines and future directions for research in this area. Keywords melanoma, LEAP 004, lenvatinib, pembrolizumab, clinical trials, cancer treatment, efficacy, safety, guidelines Takeaways The LEAP 004 study showed a 21.4% response rate. Lenvatinib is a multi-targeted VEGF receptor inhibitor with potential in melanoma. The combination of lenvatinib and pembrolizumab may increase sensitivity to PD-1 inhibitors. Toxicity is a significant concern with the lenvatinib and pembrolizumab combination. LEAP 003 did not demonstrate an improvement in overall survival compared to pembrolizumab alone. The efficacy of lenvatinib in melanoma is still being evaluated in refractory settings. There is a need for further studies to understand the mechanisms of resistance to PD-1 therapy. Guidelines for treatment may vary significantly between jurisdictions. Patient perspectives on treatment and toxicity are crucial in clinical practice. The future of lenvatinib and pembrolizumab in melanoma treatment remains uncertain. Sound Bites "What's your number of kilos you're deadlifting?" "Lenvatinib has been around for a while." "The unmet need we all know, which is anti PD-1 refractory melanoma." Chapters 00:00 Introduction and Discussion of Deadlifting 03:31 Overview of Leap004 Study and Rationale for Lenvatinib 09:22 Promising Results in Leap004 Study 15:59 Discontinuation of Leap003 Trial 19:33 Challenges with Dosing and Toxicity of Lenvatinib 22:00 Uncertainty in the Use of Lenvatinib-Pembrolizumab in PD-1 Refractory Patients

SummaryOn the heels of the great ESMO 2024 session with Toni Ribas, Inge Marie Svane, and Olivier Michielin James and Sapna discuss Prof Svane and Prof van Haanen's TIL trial, a significant study in melanoma treatment that explores the efficacy and safety of tumor-infiltrating lymphocyte (TIL) therapy compared to traditional treatments. They delve into the historical context of the trial, its design, the observed efficacy rates, potential side effects, and the implications of sex-based differences in treatment outcomes. The discussion highlights the importance of this trial in shaping future treatment strategies for melanoma and the need for further research in this area.KeywordsTIL trial, melanoma, cellular therapy, immunotherapy, efficacy, toxicity, first-line treatment, sex-based differencesTakeawaysThe TIL trial is a landmark study in melanoma treatment.TIL therapy shows a near 50% response rate in patients.The control arm of the trial has faced criticism.TIL therapy is a viable strategy for patients after PD-1 exposure.Toxicity profiles of TIL therapy need careful consideration.There is potential for TIL therapy to be used in first-line treatment.Sex-based differences in treatment outcomes are significant.The trial design raises important regulatory questions.Further research is needed to understand hormonal influences on treatment.The results of this trial could change treatment paradigms in melanoma.Sound Bites"This is the first randomized study of cellular therapy.""TIL therapy shows a near 50% response rate.""The control arm has been criticized."Chapters00:00 Introduction to the TIL trial04:08 Discussion on the efficacy of TIL therapy09:12 Considerations for regulatory approval and future research11:34 Analysis of toxicity in the TILT trial15:46 Exploring the potential of TIL therapy in the first-line setting20:12 Discussion on the feasibility of conducting larger trials with TIL therapy23:42 Sex-based differences in the response to TIL therapy27:35 Complexity of studying sex-based differences in cancer treatment31:04 Conclusion and future implications of the TILT trial33:07 Impressive Median Dose of Till Cells33:33 Administration of High-Dose IL-2

Summary In this episode of Melanoma Matters, host James Larkin uses his 1-800-Operator voice until co-host Sapna Patel reminds him to use his podium voice. There is a noisy wardrobe choice (SP) and a fact check of a fact check (JL). Sapna and James have an in-depth conversation of the Checkmate 511 study, discussing its implications for treatment regimens in melanoma. They delve into the nuances of type 1 and type 2 errors, analyze the results of the study, and consider the long-term follow-up data. The conversation also explores global perspectives on treatment practices and the importance of understanding toxicity and efficacy in clinical settings. Keywords Checkmate 511, melanoma, type 1 error, type 2 error, treatment regimens, efficacy, toxicity, global perspectives, long-term follow-up, clinical practice Takeaways Checkmate 511 is a widely cited study in melanoma treatment. Type one error relates to the alpha of the study, while type two error is related to sample size. The study showed a lower incidence of grade 3 to 5 AEs with Nivo 3 - Ipi 1 compared to Nivo 1 -Ipi 3. Long-term follow-up is crucial for understanding the efficacy of treatment regimens. Global perspectives on treatment regimens vary, especially regarding reimbursement and labeling. The study's findings have influenced practice in the U.S., despite a lack of formal publication. Concerns remain about the efficacy of lower doses in specific patient populations, such as those with brain metastases. The conversation highlights the importance of ongoing research and follow-up studies in melanoma treatment. Understanding statistical errors is essential for interpreting clinical trial results. The hosts express a desire for more comprehensive data and follow-up on the Checkmate 511 study. Sound Bites "This is a fact check of a fact check." "Type one error is related to the alpha of a study." "The incidence of grade 3 to 5 AEs was 34% with Nivo 3 -Ipi 1." Chapters 00:00 Introduction and Volume Issues 04:50 Overview of Checkmate 511 Study 09:59 Concerns about Lack of Published Follow-Up Data 16:00 Demographics and Subgroups in Checkmate 511 Study 16:44 Implementation of Inverted Dosing Regimen Globally 19:01 Caution and Considerations with Inverted Dosing Regimen 23:45 Fact Check 25:08 Comparing Regimens in the BRAF Mutant Population 29:16 Fact-Checking 'Up in the Air' 29:50 Fact Check of a Fact Check (BRAF)

Summary James is back from holiday and tells us the peak, pit, and bud of his time away. (Spoiler: the pit was NOT a broken tooth!) He also shares a tip for time management and email hygiene on holiday. Sapna makes an unfortunate wardrobe choice (noisy, not visual). In this episode of Melanoma Matters, hosts Sapna and James delve into the complexities of indirect treatment comparisons in melanoma therapy. They discuss a recently published paper comparing nivolumab plus relatlimab versus nivolumab plus ipilimumab, exploring the statistical methodologies, clinical implications, and biological plausibility of the findings. The conversation highlights the importance of understanding treatment options, patient selection, and future directions in melanoma treatment strategies. Keywords melanoma, indirect treatment comparison, nivolumab, relatlimab, ipilimumab, clinical trials, biomarkers, treatment strategies, patient care, oncology Takeaways Indirect treatment comparisons are a valid methodology. Statistical methodologies can be complex but are essential for comparisons. The efficacy of treatments can vary based on patient characteristics. Biological plausibility is crucial in interpreting treatment outcomes. LDH levels can be significant biomarkers in treatment decisions. Ipilimumab plus nivolumab is considered a potent treatment regimen. Patient experience and clinical data inform treatment choices. Future strategies may involve combining therapies for better outcomes. Understanding the nuances of clinical trials is vital for practitioners. Reimbursement discussions may hinge on the findings of such studies. Sound Bites "I don't understand the statistics and the principles behind it." "It's an accepted methodology, I think is the first thing to say." "It's a reasonable exercise." Chapters 00:00 Introduction and Rapid Fire Questions 06:49 Understanding Indirect Treatment Comparison 11:55 Comparison of Nevolumab Plus Relatlimab vs. Nevolumab Plus Ipilimumab 14:40 LDH as a Biomarker in Melanoma 20:28 Benefit of Ipnevo for BRAF Mutated Patients 23:17 Considerations for Targeted Therapy Before Immunotherapy

SummaryOur hosts guilty pleasures - junk food and South Park! Endless laughs about South Park...In this episode of Melanoma Matters, Sapna Patel and James Larkin discuss the complexities of end-of-life care in patients with melanoma. They explore the importance of early conversations about treatment options, the role of palliative care, and the emotional and cultural aspects of dying. The discussion emphasizes the need for clear communication with patients regarding their treatment goals and the transition to palliative care as the disease progresses.Keywordsmelanoma, end of life, palliative care, treatment decisions, steroid use, goals of care, symptom management, cultural perspectivesTakeaways End-of-life conversations should start early in treatment. Palliative care teams can provide essential support. Patients often feel better initially on targeted therapies. Cultural perspectives influence how patients view death. It's crucial to listen to patients' feelings about their treatment. Transitioning to palliative care requires careful planning. Symptom management is a key focus in end-of-life care. Communication with families is vital for understanding wishes. Patients may resist discussions about end-of-life care. Healthcare providers must be comfortable discussing death.TitlesThe Importance of Early Goals of CareNavigating End of Life in Melanoma CareSound Bites"What's the minimal amount of therapy?""Transitioning to a different phase of treatment.""It's important to have those conversations early."Chapters00:00 Introduction and Guilty Pleasures05:21 Transitioning to Non-Curative Treatment09:39 Early Goals of Care Discussions11:55 The Limitations of BRAF Targeted Therapy14:07 Connecting Patients to Palliative Care15:59 Options for End-of-Life Care16:29 Challenges of Delivering Nursing Care at Home17:32 Limitations of Hospice Care19:50 The Role of Targeted Therapies in Palliative Care24:06 Managing Symptoms with Steroids33:20 Medical Assistance in Dying